−13.73 USD
−4.00 M USD
0.00 USD
2.62 M
About TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0A8D is 1.27 USD — it has increased by 8.01% in the past 24 hours. Watch TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) stocks are traded under the ticker 0A8D.
0A8D stock has risen by 6.97% compared to the previous week, the month change is a 2.90% rise, over the last year TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) has showed a −73.90% decrease.
0A8D reached its all-time high on Nov 2, 2021 with the price of 287.70 USD, and its all-time low was 1.11 USD and was reached on Nov 29, 2024. View more price dynamics on 0A8D chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0A8D stock is 19.06% volatile and has beta coefficient of −0.01. Track TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) there?
Today TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) has the market capitalization of 3.22 M, it has increased by 2.59% over the last week.
Yes, you can track TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
0A8D net income for the last quarter is −1.93 M USD, while the quarter before that showed −9.57 M USD of net income which accounts for 79.83% change. Track more TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) financial stats to get the full picture.
No, 0A8D doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 30, 2025, the company has 6.00 employees. See our rating of the largest employees — is TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) on this list?
Like other stocks, 0A8D shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) stock shows the sell signal. See more of TNF PHARMACEUTICALS INC EFFEC COM NPV (POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.